SCHEMBL2567142

SCHEMBL2567142

COC(=O)C1=C(CCl)NC(=O)NC1c1ccc(F)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.58
MAPT P10636 2/20 0.58
TDP1 Q9NUW8 2/20 0.58
KDM4E B2RXH2 1/20 0.58
MITF O75030 1/20 0.58
ALOX15 P16050 1/20 0.58
KLF5 Q13887 1/20 0.58
LMNA P02545 1/20 0.56
GLA P06280 1/20 0.56
CA12 O43570 1/20 0.56
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
CA7 P43166 1/20 0.56
CA9 Q16790 1/20 0.56
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
L3MBTL1 Q9Y468 1/20 0.54
RXFP1 Q9HBX9 1/20 0.53
GAA P10253 2/20 0.52
TP53 P04637 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4503574 0.88 ALDH1A1 (0.58) ALDH1A1MAPTTDP1KDM4EMITF
SCHEMBL10129233 0.79 GAA (0.59) ALDH1A1MAPTTDP1KDM4EMITF
SCHEMBL8690693 0.76 CTDSP1 (0.53) ALDH1A1MAPTTDP1KDM4EMITF
SCHEMBL6645152 0.75 CTDSP1 (0.58) ALDH1A1MAPTTDP1KDM4EMITF
SCHEMBL7082385 0.75 CTDSP1 (0.58) ALDH1A1MAPTTDP1KDM4EMITF
SCHEMBL7082388 0.75 CTDSP1 (0.58) ALDH1A1MAPTTDP1KDM4EMITF
SCHEMBL2567572 0.73 GRK2 (0.63) ALDH1A1LMNAGLA
SCHEMBL10112947 0.72 HSD17B10 (0.69) ALDH1A1KDM4EALOX15KMT2AL3MBTL1
SCHEMBL19752622 0.72 MAPT (0.78) ALDH1A1MAPTLMNACA12CA1
SCHEMBL19752649 0.72 MAPT (0.78) ALDH1A1MAPTLMNACA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1633740-B1 5-(ACYLAMINO)INDAZOLE DERIVATIVES AS KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2011-11-09 EP disclosed
US-7560467-B2 Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2009-07-14 US disclosed
EP-1633740-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2008-11-19 EP disclosed
US-20070099944-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2007-05-03 US disclosed
EP-1633740-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2006-03-15 EP disclosed
WO-2004112719-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099944-A1 Chemical compounds ROCK1, ROCK2, CIT ALDH1A1 1692/4885MAPT 516/4885TDP1 818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.